Immunization of patients with sjögren's syndrome with pneumococcal polysaccharide vaccine
SourceArthritis & Rheumatism
Google Scholar check
MetadataShow full item record
Thirty‐two patients with Sjögren's syndrome were randomly selected to receive either multivalent pneumococcal polysaccharide vaccine or saline placebo in a double‐blind study. Among placebo treated patients, levels of antipneumococcal antibodies remained constant. Immunized patients developed significant elevations of antibody concentrations against all 12 capsular serotypes measured. Levels fell, but persisted above baseline, for 8 of the serotypes 6 months after immunization. During the 6‐month study no clinical or serologic evidence of disease exacerbation occurred in either group. We conclude that pneumococcal vaccine can be safely and successfully administered to patients with Sjögren's syndrome. Copyright © 1980 American College of Rheumatology
Showing items related by title, author, creator and subject.
Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: Implications in HIV-1 vaccines Hassapis, K. A.; Stylianou, Dora C.; Kostrikis, Leontios G. (2014)Inovirus-associated vectors (IAVs) are engineered, non-lytic, filamentous bacteriophages that are assembled primarily from thousands of copies of the major coat protein gp8 and just five copies of each of the four minor ...
Hassapis, K. A.; Kostrikis, Leontios G. (2013)Antigen-presenting viral vectors have been extensively used as vehicles for the presentation of antigens to the immune system in numerous vaccine strategies. Particularly in HIV vaccine development efforts, two main viral ...
Pentheroudakis, George; Pavlidis, Nicholas (2003)